Elisabeth Wassner-Fritsch

发表

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

G. Salles, R. Bouabdallah, P. Feugier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

G. Salles, H. Tilly, P. Solal-Céligny, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone

E. Kimby, J. Gribben, L. Sehn, 2016, Annals of Hematology.

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

J. Gribben, G. Salles, L. Sehn, 2015, Blood.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

R. Bouabdallah, M. Hallek, V. Leblond, 2014, Blood.

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

E. Hoster, J. Gribben, L. Sehn, 2019, Leukemia.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

J. Gribben, G. Salles, L. Sehn, 2016, The Lancet. Oncology.

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

G. Salles, J. Radford, R. Marcus, 2013, Blood.

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma

M. Dyer, P. Marlton, M. Dreyling, 2016, Haematologica.

Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)

G. Salles, L. Sehn, G. Fingerle-Rowson, 2014 .

Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

G. Salles, J. Radford, R. Marcus, 2011 .

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

J. Gribben, G. Salles, L. Sehn, 2016 .

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

G. Salles, R. Bouabdallah, P. Feugier, 2011 .

Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM

R. Vij, H. Hamidi, A. Raval, 2023, Frontiers in immunology.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.